IE
CGON icon

Israel Englander’s CG Oncology CGON Stock Holding History

Israel Englander’s Portfolio CGON Stock Details CGON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.42M Hold
20,000
– – ﹤0.01% 4092
2026
Q1 		$1.35M Sell
20,000
-50,000
-71% -$2.83M ﹤0.01% 4164
2025
Q4 		$2.91M Buy
+70,000
New +$2.9M ﹤0.01% 3600

Other funds holding CGON

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Israel Englander's CGON Position: Q1 2026 in Review

Israel Englander sold out of CG Oncology (CGON) in Q1 2026, closing a stake of 91,454 shares — an estimated $5.18M sold.

Israel Englander first reported a position in CGON in Q1 2024 and held it in 7 quarters. The position peaked at $25M in Q2 2025. 233 funds tracked by Wall St. Rank hold CGON as of Q1 2026.

  • Israel Englander reported no remaining CG Oncology position as of Q1 2026 after selling out during the quarter.
  • Israel Englander sold 91,454 CG Oncology shares in Q1 2026, an estimated $5.18M.
  • Israel Englander first reported a position in CG Oncology in Q1 2024 and held it in 7 quarters.
  • Israel Englander's CG Oncology position peaked at $25M in Q2 2025.
  • 233 funds tracked by Wall St. Rank held CG Oncology as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.